Stocks · Theme
Medtech, diagnostics & life-science tools stocks · 81 research notes
81 Medtech, diagnostics & life-science tools stocks moving on the same story, each with a dated research note: thesis, kill line and next catalyst.
Active themeStage: maturing, as of 15 November 2026.
All 81 have a dated research note with a published kill line: the note's own test, stated in advance, of what would prove it wrong: a price level, a business fact, or both.
All stocksAZTAAzentaHigh Azenta is more likely to beat the S&P 500 over three months because its fiscal 2027 plan, issued 10 November 2026, adds 3% to 5% organic growth and a wider margin. The fiscal first-quarter report, expected around early February 2027, shows…ADPTAdaptive BiotechnologiesMedium Adaptive Biotechnologies is more likely than not to beat the S&P 500 over three months because clonoSEQ tests rose 46% in the third quarter of 2026 and MRD revenue guidance rose to $276–286 million. Medicare's final 2027 lab rates,…AVTRAvantorMedium Avantor's lab-supply volumes are growing again, with Q3 2026 organic growth of 5.2% and a raised FY2026 outlook, but distribution margins fell. The 8 December 2026 Investor Day shows whether margin targets support further gains in the…AXGNAxogenMedium Axogen's nerve-repair revenue grew 26.2% last quarter and a $754 million prostate market sits outside guidance, giving the shares a modest edge over the S&P 500; the Q4 2026 report settles whether revenue excluding BioCircuit reaches the…CDNACareDxMedium CareDx's shares are modestly more likely than not to beat the S&P 500: transplant testing revenue grew 39% in the third quarter excluding catch-up collections and 2026 guidance rose to $520–530 million. CMS's final 2027 Medicare rates, due…CRLCharles River Laboratories InternationalMedium Charles River Laboratories' preclinical recovery passed its 4 November 2026 test with 4.7% organic growth, a 1.09 book-to-bill and raised guidance, and the $470 million Frontage deal adds clinical testing; the fourth-quarter report,…CSTLCastle BiosciencesMedium Castle Biosciences raised 2026 revenue guidance to $385–395 million and held its 50–52% TissueCypher volume growth plan; the fourth-quarter report, expected around 26 February 2027, shows whether that test offsets weaker melanoma volume.DHRDanaherMedium Danaher's shares have a modest edge over the S&P 500 because mid-teens bioprocessing orders should reach revenue in 2027. Formal 2027 guidance in late January settles whether growth meets or beats the 4%–5% starting point that management…DXCMDexComMedium Dexcom's raised 2026 outlook and 25.3% third-quarter operating margin give the shares a modest edge after a diabetes-device sell-off erased the post-report gain. A Medicare coverage decision for non-insulin type 2 diabetes, which…EMBCEmbectaMedium Embecta Corp. shares are modestly favored to beat the S&P 500 as higher margins and debt repayment outweigh shrinking U.S. pen-needle sales; the fiscal 2026 report and first fiscal 2027 outlook on 24 November 2026 settle it.ENOVEnovisMedium Enovis Corporation's orthopedic turnaround passed its 5 November 2026 test with 4.6% organic growth, raised earnings guidance and a $200 million buyback. The late-February 2027 full-year report shows whether about 5% growth and at least…GKOSGlaukosMedium Glaukos's iDose TR glaucoma implant and Epioxa keratoconus therapy lifted third-quarter 2026 sales 58% to $211.0 million, giving the shares a modest edge on a $1 billion 2027 outlook. Medicare's pending iDose TR coverage decision and…HAEHaemoneticsMedium Haemonetics' plasma revenue grew 17.7% organically before the CSL Plasma conversion added much, so the larger CSL gain lies ahead; the fiscal third-quarter report around 4 February 2027 shows whether it arrives without a further margin cut.HTFLHeartflowMedium Heartflow's shares are modestly more likely to beat the S&P 500 over three months: third-quarter revenue rose 57% and the 2026 outlook was raised to $262–264 million, though the shares fell 19.13% on 13 November 2026. The fourth-quarter…ICLRICONMedium ICON plc's orders have recovered into fee-earning work, with a third-quarter direct-fee book-to-bill near 1.3, giving the shares a modest edge over the S&P 500 while earnings per share still trail last year. The fourth-quarter report and…IQVIQVIA HoldingsMedium IQVIA's clinical-research bookings are outpacing revenue, with third-quarter 2026 bookings up 15% at a 1.2x book-to-bill and guidance raised. The 1 December 2026 investor day decides whether that becomes faster 2027 revenue growth.LHLabcorp HoldingsMedium Labcorp's 11.5% Central Labs growth and raised 2026 guidance make its shares modestly more likely to beat the S&P 500 over three months. Final 2027 Medicare lab rates, due from CMS in late November 2026, test the case, and the February…MTDMettler-Toledo InternationalMedium Mettler-Toledo's third-quarter beat and a 2027 earnings guide above estimates support modest outperformance against the S&P 500; the fourth-quarter report, expected in early February 2027, settles whether about 5% sales growth holds.MYGNMyriad GeneticsMedium Myriad Genetics shares look modestly more likely to beat the S&P 500 after third-quarter revenue per test rose 1% and the 2026 revenue guide was raised; the cost of the 2 November 2026 network intrusion to testing volumes and patient data…NEONeoGenomicsMedium NeoGenomics' cancer-testing turnaround is lifting profit faster than revenue, but clinical test volume grew only 1.8% in the third quarter. Pending Medicare decisions on RaDaR ST and the fourth-quarter report will show whether volume…RCELAvita MedicalMedium AVITA Medical's shares are modestly more likely than not to beat the S&P 500 after 53% revenue growth and a raised $92–94 million 2026 guide; the fourth-quarter report shows whether promised cash-flow breakeven arrives.SGHTSight SciencesMedium Sight Sciences' TearCare dry-eye treatment is becoming a second revenue line beside its OMNI glaucoma devices, giving the shares a modest edge over the S&P 500: third-quarter dry-eye sales rose 45% to $3.9 million, and UBS raised its…SIBNSI-BONEMedium SI-BONE's recovery case holds after a third-quarter beat and a final 2027 Medicare office payment, giving its shares a modest edge over the S&P 500. Late-February results settle it by showing whether fourth-quarter growth topped 20%.TMOThermo Fisher ScientificMedium Thermo Fisher Scientific's 6% third-quarter organic growth, raised 2026 outlook and $5 billion buyback give the shares a modest edge over the S&P 500. The late-January 2027 report and first 2027 guidance decide whether that growth holds.UFPTUFP TechnologiesMedium UFP Technologies is growing above its own target, with 11.1% Q3 2026 organic growth against a 6%–9% goal, while delayed Dominican Republic transfers hold margins back. The Q4 report, expected around March 2027, shows whether growth stays…VCELVericelMedium Vericel's knee-cartilage implant MACI is growing above 20% a year and the 5 November 2026 report raised 2026 revenue guidance to $344–346 million. The fourth-quarter report settles the case by showing whether MACI reaches about $102…BSXBoston ScientificLow Boston Scientific shares are more likely to lag the S&P 500 over three months: a cyberattack, falling Watchman sales and lost ablation share turned fourth-quarter sales guidance negative. The fourth-quarter report expected around 4…CERTCertaraLow Certara's software sales have re-accelerated, but at $11.73 the shares already trade near analysts' raised targets, so they are more likely to lag the S&P 500 over the next three months. The fourth-quarter report and 2027 outlook, expected…FTREFortrea HoldingsLow Fortrea's shares are more likely to lag the S&P 500: margins are improving, but a $558 million backlog cut clouds 2027 revenue. Backlog growth from $7,316 million at the fourth-quarter report settles the case.GRALGRAILLow GRAIL's shares are more likely to lag the S&P 500 over three months: after a 78.8% three-month rise, approval of the Galleri cancer test looks largely priced in while the company cut its 2026 Galleri revenue outlook and per-test prices…ISRGIntuitive SurgicalLow Intuitive Surgical's shares look more likely to lag the S&P 500 because US procedure growth slowed to 10% and instrument revenue per procedure is set to fall 3%–5% from 2027. The mid-January 2027 preliminary procedure count will show…JNJJohnson & JohnsonLow Johnson & Johnson's drug approvals keep coming, but weak medical devices and $1.36 per share of 2027 deal dilution leave the shares more likely to lag the S&P 500. The 8 December 2026 business review and January 2027 guidance settle it.KIDSOrthoPediatricsLow OrthoPediatrics shares are more likely to lag the S&P 500 because the $33.67 close on 11 November 2026 sits above six of seven post-report analyst targets despite 19% sales growth. Preliminary fourth-quarter revenue, expected about…NTRANateraLow Natera's shares are more likely to lag the S&P 500 into early 2027, because an abrupt CEO change on 5 November 2026 outweighed a revenue beat and raised guidance. The Q4 report, estimated for late February 2027, tests Signatera growth…QDELQuidelOrthoLow QuidelOrtho's shares are more likely to lag the S&P 500: third-quarter revenue fell 11.6% and net leverage rose to 4.5 times while the point-of-care sale meant to cut $2.94B of borrowings is still unsigned. A signed deal or the…TEMTempus AILow Tempus AI shares are more likely to lag the S&P 500 over the next three months: third-quarter revenue of $411.5 million matched forecasts and the 2026 guide rose only at its low end, after a 46.3% three-month gain. The Personalis vote on…TWSTTwist BioscienceLow Twist Bioscience shares are more likely to lag the S&P 500 because its fiscal 2027 outlook assumes AI drug-discovery revenue grows far slower than the 175% of fiscal 2026. The fiscal first-quarter report expected in early February 2027…TXG10x GenomicsLow 10x Genomics' shares are more likely to lag the S&P 500 over the next three months: third-quarter revenue grew 1% and analysts cut targets after the report. The fourth-quarter Atera count against a plan of about 50 units settles it.ATRCAtriCureMedium AtriCure's 3 November 2026 report backed its profit-led re-rating with 15.0% revenue growth and adjusted EPS guidance raised to $0.40–$0.46, so the shares modestly favour beating the S&P 500. The fourth-quarter report in early 2027 decides…BFLYButterfly NetworkMedium Butterfly Network's chip-licensing business beat guidance in the third quarter, and the shares are modestly more likely than not to beat the S&P 500 over three months; the fourth-quarter report, expected around late February 2027, settles…BLLNBillionToOneMedium BillionToOne is more likely to beat the S&P 500 over three months: it beat and raised on 4 November 2026 (revenue $123.0 million, up 47%) and is profitable with $561.5 million in cash. The fourth-quarter report, expected around March 2027,…CBLLCeriBellMedium CeriBell's delirium monitor, launched 2 November 2026, should add headband usage to a seizure-monitoring business growing 30%, so the shares are modestly more likely to beat the S&P 500 over three months; 2027 guidance with the…KMTSKestra Medical TechnologiesMedium Kestra Medical Technologies is modestly more likely than not to beat the S&P 500 over three months: revenue grew 60% and gross margin reached 56.5%. The fiscal second-quarter report, estimated for about 10 December 2026, tests the $141…PLSEPulse BiosciencesMedium Pulse Biosciences is modestly more likely to lead the S&P 500 because $189.2 million of cash funds its atrial-fibrillation catheter through pivotal follow-up. The persistent-AF study filing guided for the fourth quarter of 2026 and…RVTYRevvityMedium Revvity's third-quarter report put Life Sciences back in growth (+9% pro forma organic) and lifted full-year guidance, which makes the shares modestly more likely than not to beat the S&P 500. The 13 November 2026 Investor Day tests…SENSSenseonics HoldingsMedium Senseonics' third-quarter revenue beat and second 2026 guidance raise give the shares a modestly better-than-even case to beat the S&P 500; the fourth-quarter iLet launch and the full-year report, which must deliver the $68–70 million…TNDMTandem Diabetes CareMedium Tandem Diabetes Care is modestly more likely to beat the S&P 500 over three months: management said on 5 November 2026 that tubeless Mobi is in late FDA review with approval expected in the fourth quarter. Clearance by 31 December 2026…ABTAbbott LaboratoriesLow Abbott Laboratories' shares are more likely to lag the S&P 500 over three months: the 2026 comparable growth guide was cut to about 6.0% on 21 October 2026, and the late-January 2027 fourth-quarter report and 2027 guidance decide whether…AIFFFirefly NeuroscienceLow Firefly Neuroscience's third-quarter revenue rose to $647,000, but cash fell to $8.0 million with going-concern doubt unresolved, and the shares at $0.96 are more likely to lag the S&P 500; unannounced revenue terms from its partnerships…AVRAnteris Technologies GlobalLow Anteris Technologies is more likely to lag the S&P 500 over three months: its DurAVR heart-valve trial is funded, but spending is rising and a $250 million stock-sale program is open; the December-quarter cash report in late January 2027…BAXBaxter InternationalLow Baxter International's shares are more likely to lag the S&P 500: sales growth recovered to 5%, but third-quarter margins fell and 2027 carries cost headwinds. The February 2027 guidance settles whether earnings follow sales.BBNXBeta BionicsLow Beta Bionics' shares are more likely to lag the S&P 500 while iLet buyers wait for the Mint patch pump's Q1 2027 launch; Mint shipments and coverage at the early-2027 report settle it.BVSBioventusLow Bioventus's shares depend on its strategic review ending in a sale, and the 2 November 2026 cut to 2026 sales guidance weakens the standalone fallback; a signed deal or an end-of-review notice settles it, and the shares are more likely to…CAICaris Life SciencesLow Caris Life Sciences' third-quarter beat and raised 2026 revenue guidance were offset by slower 27% growth, a lower gross margin and negative free cash flow, so the shares look more likely to lag the S&P 500; the fourth-quarter report,…CERSCerusLow Cerus Corporation's red-cell trial met its primary endpoint but the shares still fell to $1.95 on 10 November 2026; Q4 product revenue against the reaffirmed $229–231M guide, and any use of the new $150M shelf, settle the case.CLPTClearPoint NeuroLow ClearPoint Neuro is more likely to lag the S&P 500 over three months: its fortunes ride on uniQure's Huntington's application, and its own 2026 revenue guide has been cut twice. The full-year report and the FDA's 1 May 2027 target date…CNMDCONMEDLow CONMED Corporation's shares are more likely to lag the S&P 500 over three months: the price leans on an unconfirmed July sale report while the 28 October 2026 report trimmed organic growth guidance. A confirmed deal or the fourth-quarter…CTKBCytek BiosciencesLow Cytek Biosciences' revenue growth slowed to 2% in the third quarter and product sales fell, so the shares look more likely to lag the S&P 500 than lead it. Fourth-quarter revenue against the $208 million–$211 million outlook settles it.DDD3D SystemsLow 3D Systems met its Q3 revenue guidance, but a Q4 outlook below estimates, a $42.5 million share-sale program and a debt-for-equity exchange keep the shares more likely to lag the S&P 500; Q4 revenue and dilution settle it.FRNMFreenomeLow Freenome's shares are rated more likely to lag the S&P 500: its 10 November 2026 report showed $430.0 million of cash, but $180.0 million of $183.5 million quarterly revenue was a one-off Abbott collaboration payment. The December 2026…GHGuardant HealthLow Guardant Health's Shield revenue is growing fast, but patent losses, wider cash-burn guidance and a new $500 million convertible note sale make the shares more likely to lag the S&P 500; the report expected around 18 February 2027 settles…IARTIntegra LifeSciences HoldingsLow Integra LifeSciences' shares are more likely to lag the S&P 500 over three months: 2026 guidance held, but fourth-quarter guidance missed estimates. The SurgiMend relaunch targeted for 31 December 2026 and the Cincinnati plant's 2027…ILMNIlluminaLow Illumina's shares are more likely to lag the S&P 500 over the next three months: third-quarter organic growth was 4.8%, China sits outside the clinical growth rate, and on 10 November 2026 management declined to guide 2027. The…INGNInogenLow Inogen's shares are more likely to lag the S&P 500 after its first report as a pure oxygen-concentrator maker showed revenue down 2.4% and a lower outlook, leaving a new CEO's $20 million cost program to carry the case. The fourth-quarter…INSPInspire Medical SystemsLow Inspire Medical Systems is more likely to lag the S&P 500 over three months: revenue fell 7.9% in the third quarter and 2026 guidance was only narrowed. The fourth-quarter report, expected around February 2027, settles whether the decline…MMEDMiniMed GroupLow MiniMed Group's diabetes-device sales grew 15.8% organically in the July quarter, but the shares ($17.88 close on 12 November 2026, below the $20.00 IPO price) are more likely to lag the S&P 500; the 24 November 2026 fiscal second-quarter…NEOGNeogenLow Neogen's shares are more likely to lag the S&P 500 into early 2027: they broke below their post-results low on 12 November 2026 as the Zoetis Genomics sale that funds debt reduction slipped to early 2027. The fiscal second-quarter report…NVCRNovoCureLow NovoCure's core glioblastoma business beat and raised in the third quarter, but the FDA's 9 November 2026 Not Approvable letter for Optune Mya removes a 2027 brain-metastases launch; the outcome of the company's talks with the FDA settles…OBIOOrchestra BioMed HoldingsLow Orchestra BioMed is more likely to lag the S&P 500 over three months: the BACKBEAT hypertension data that decide the case are planned for the Heart Rhythm 2027 meeting in May 2027, after that window, and the shares are up 39.5% in three…PACBPacific Biosciences of CaliforniaLow Pacific Biosciences' shares are more likely to lag the S&P 500 after Q3 2026 showed gross margin falling to 33% from 41% and a guide cut to $155–160M, followed by a $100M at-the-market stock program. The fourth-quarter report, expected in…PRPOPrecipioLow Precipio's shares are more likely to lag the S&P 500 after a jump to $24.80 on 11 November 2026, because third-quarter revenue of $7.331 million showed steady growth with no new acceleration. The fourth-quarter report, expected around…QTRXQuanterixLow Quanterix's third-quarter report beat on revenue but cut the year-end cash forecast to about $70 million and pushed the spatial panels to early 2027, so the shares still lack a result that supports a recovery; the fourth-quarter report…SEERLow Seer, Inc. closed at $1.61 on 10 November 2026 after its board rejected both take-private proposals and the third-quarter report cut 2026 revenue guidance to $13.5-14.5 million. Cash of $198.1 million and the year-end patent ruling now…SMTISanara MedTechLow Sanara MedTech is more likely to lag the S&P 500 over three months: its sale to MiMedx has no closing date after the FTC's 15 October 2026 Second Request, and the 12 November 2026 guidance cut weakens the fallback value. FTC clearance or a…SOPHSOPHiA GENETICS SALow SOPHiA GENETICS' third-quarter report showed healthy customer spending but held its revenue range at the upper end of $94–96 million, so the shares are more likely to lag the S&P 500; the fourth-quarter report decides it.STAASTAAR SurgicalLow STAAR Surgical's third-quarter report showed China demand holding up (underlying China sales +31%) but supply and gross margin still lagging; the shares closed at $23.87 on 10 November 2026, and the fourth-quarter report decides whether…TKNOAlpha TeknovaLow Alpha Teknova's third-quarter revenue rose 22% and it raised 2026 guidance to $46-48 million, but the shares at $8.55 already sit near the $8.75 consensus target; 2027 guidance due with full-year results in early 2027 decides the next move.VCYTVeracyteLow Veracyte's profitable test business was repriced after its 4 November 2026 report showed Decipher prostate growth of 12% and a mid-single-digit 2027 revenue preview. The fourth-quarter Decipher volume report decides whether growth has…VREXVarex ImagingLow Varex Imaging is a deal-completion case capped at Teledyne's $18.90 cash price; the UK and US reviews ending 18 November 2026 and 19 November 2026 decide whether completion in early 2027 stays on track.XGNExagenLow Exagen's shares are more likely to lag the S&P 500 after a third quarter with about 2% test-volume growth, a wider loss and a new $150 million shelf; a Medicare coverage ruling or full-year revenue above guidance would test that view.XRAYDentsply SironaLow Dentsply Sirona's shares are more likely to lag the S&P 500 over three months: the 5 November 2026 report missed estimates and cut fiscal 2026 adjusted EPS guidance to $1.20–$1.30. The fourth-quarter report, expected around 26 February…